# Tegafur + Gimeracil + Oteracil K

## TS-1 20mg

##### 臨採

| TAH Drug Code      | [OTS1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OTS1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Post-op adjuvant chemotherapy for locally advanced [stage II (excluding T1), IIIA or IIIB) gastric cancer. Treatment for advanced Inoperable or recurrent gastric cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | In general, for adults, the initial dose is determined based on body surface area (BSA). BSA < 1.25 m2: 40 mg/dose (80 mg/day); BSA 1.25 to < 1.5 m2: 50 mg/dose (100 mg/day); BSA >= 1.5 m2: 60 mg/dose (120 mg/day). Administer TS-1 capsule orally twice daily, after breakfast and dinner, for 28 consecutive days (4 weeks), followed by a 14-day (2 weeks) rest for a 6-week course. For colorectal cancer, TS-1 administered orally twice daily on days 1 through 14 of a 28-day cycle in combination with irinotecan 125 mg/m2 IVD once every 14 days on day 1 and 15. TS-1 must NOT be taken with other fluoropyrimidine-group anti-cancer drug. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Severe bone marrow depression, renal & hepatic disorder. Treatment with other fluoropyrimidine-group anticancer drugs (including combination therapies) & flucytosine. Pregnancy & lactation.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Leukopenia, decreased Hb, thrombocytopenia, decreased neutrophil count; increased AST/ALT, bilirubin & creatinine; glycosuria, stomatitis, anorexia, nausea, vomiting, diarrhea, abdominal pain, constipation, rash, pigmentation, lacrimation, taste abnormality, dizziness, decreased weight, pyrexia, nasopharyngitis & fatigue.                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tegafur-+-gimeracil-+-oteracil-k-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

